SpyGlass Pharma to Participate in Upcoming Investor Conferences
Rhea-AI Summary
SpyGlass Pharma (Nasdaq: SGP) announced that its executive management will participate in three upcoming investor events focused on healthcare and ophthalmology.
These include the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 4, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. All sessions feature fireside chats or a corporate presentation, with live webcasts and replays available on the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – SGP
In the May 21 session, SGP gained 0.73%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.2% during that session. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences:
Stifel 2026 Virtual Ophthalmology Forum
Date: Tuesday, May 26, 2026
Time: 2:00 p.m. ET
Format: Fireside Chat
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 2:35 p.m. ET
Format: Fireside Chat
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Time: 10:40 a.m. ET
Format: Corporate Presentation
A live webcast and subsequent replay of each presentation can be accessed via the Investor Relations section of the Company website at www.spyglasspharma.com.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.
Media Contact:
Nami Surendranath
+1 (402) 507-6757
nsurendranath@dnacommunications.com
Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com
